Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 2 chart positions in 2 markets.
By chart position
- 🇺🇸US · Non-Profit#10030K to 100K
- 🇨🇭CH · Non-Profit#843K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
17K to 55K🎙 ~2x weekly·5 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
33K to 110K🇺🇸91%🇨🇭9% - Active Followers
Loyal subscribers who consistently listen
18K to 61K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Navigating Value and Policy in U.S. Cancer Care and Pharma Pricing
Apr 30, 2026
34m 48s
Most Favored Nation and What's Next
Apr 14, 2026
33m 49s
AI Revolution: Breaking Pharmacy Chains with Harry Travis, BS Pharm, MBA, and Ira Klein, MD, MBA, FACP
Mar 17, 2026
22m 28s
Consolidation Versus Independence in Cancer Care
Feb 24, 2026
25m 10s
Insights from JP Morgan 2026 with Liz Fowler, PhD, JD
Feb 8, 2026
25m 20s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | |
|---|---|---|---|---|
| 4/30/26 | Navigating Value and Policy in U.S. Cancer Care and Pharma Pricing | International reference pricing could drastically reshape drug costs in the U.S. and threaten domestic innovation. In this latest episode of AVBCC’s Value-Based Voices, join Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc., and Member of the AVBCC Board of Directors, and healthcare policy strategist Brian Reid, MS, Founder of Reid Strategic, as they unpack the complex debate over the proposed international MFN models like Globe, Guard, and Generous — and whether they will do m... | 34m 48s | |
| 4/14/26 | Most Favored Nation and What's Next | Most companies, and even policymakers, are betting big on importing international drug prices — but what does that really mean for cancer care in America? In this episode of Value-Based Voices, Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc., dives into the evolving landscape of drug pricing reforms, unlocking why policies like the Most Favored Nation (MFN) and the Global Benchmark could reshape how medicines reach patients, providers, and payers. You’ll discover ... | 33m 49s | |
| 3/17/26 | AI Revolution: Breaking Pharmacy Chains with Harry Travis, BS Pharm, MBA, and Ira Klein, MD, MBA, FACP | There are countless opportunities hidden in the data-driven tasks pharmacists do every day, and AI is ready to unlock them. But what happens when automation dramatically increases productivity in pharmacy, and how do regulations, workforce, and patient care evolve in tandem? In this latest episode of AVBCC's Value-Based Voices, join Ira Klein , MD, MBA, FACP, VP Medical Affairs, Payer Relations, Tempus Labs, and AI innovator Harry Travis, BS Pharm, MBA, President, The Travis Group, LLC, as th... | 22m 28s | |
| 2/24/26 | Consolidation Versus Independence in Cancer Care | Is consolidation in cancer care truly the best path forward, or does independence offer greater benefits? In this episode of Value-Based Voices Sarah Alwardt, PhD, President, Avalere Health, and Jeff Patton, MD, CEO, OneOncology, discuss the nuances of consolidation versus independence in cancer care, the impact of policy and capital access, and the future of value-based oncology. Gain insights into sustainable models, data utilization, and patient-centered strategies. Contact Value-Based Vo... | 25m 10s | |
| 2/8/26 | Insights from JP Morgan 2026 with Liz Fowler, PhD, JD | Commercial health plans may have been missing from J.P. Morgan 2026, but government had a big presence! Value-Based Voices host Burt Zweigenhaft, PhD, and nationally recognized health policy expert Liz Fowler, PhD, JD, share their observations from this year’s meeting and key insights around most-favored nation prescription drug pricing, 340B, PBMs, Medicare site neutrality, AI, and of course value-based care. Contact Value-Based Voices - Follow AVBCC on LinkedIn - View our podca... | 25m 20s | |
| 2/8/26 | More Insights from JP Morgan 2026 with Jeff Berkowitz, JD | Where was the drama at JP Morgan this year? Host Burt Zweigenhaft, PhD, and seasoned healthcare executive Jeff Berkowitz, JD, debate why the 2026 meeting seemed to be missing its normal electricity. They also share their thoughts around challenges with direct-to-patient models, most-favored-nation and its impact on product launch and pricing both in the US and Europe, and how AI may or may not be the key to finally achieving value-based outcomes. Contact Value-Based Voices - Follow AVBC... | 39m 07s |
Showing 6 of 6
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.